ZA200505031B - 4-(2-Phenyloxyphenyl)-piperidine or -1,2,3,6-tetrahy-dropyridine derivatives as serotonin reuptake inhibitors - Google Patents
4-(2-Phenyloxyphenyl)-piperidine or -1,2,3,6-tetrahy-dropyridine derivatives as serotonin reuptake inhibitors Download PDFInfo
- Publication number
- ZA200505031B ZA200505031B ZA200505031A ZA200505031A ZA200505031B ZA 200505031 B ZA200505031 B ZA 200505031B ZA 200505031 A ZA200505031 A ZA 200505031A ZA 200505031 A ZA200505031 A ZA 200505031A ZA 200505031 B ZA200505031 B ZA 200505031B
- Authority
- ZA
- South Africa
- Prior art keywords
- alk
- hydrogen
- compound
- phenyl
- cycloalk
- Prior art date
Links
- 239000003772 serotonin uptake inhibitor Substances 0.000 title description 5
- YWIYMDPWBAXEKQ-UHFFFAOYSA-N 4-(2-phenoxyphenyl)piperidine Chemical compound C1CNCCC1C1=CC=CC=C1OC1=CC=CC=C1 YWIYMDPWBAXEKQ-UHFFFAOYSA-N 0.000 title description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 122
- 239000001257 hydrogen Substances 0.000 claims description 122
- 150000001875 compounds Chemical class 0.000 claims description 108
- 150000002431 hydrogen Chemical class 0.000 claims description 89
- -1 Ci.¢-alkyl Inorganic materials 0.000 claims description 64
- 229910052736 halogen Inorganic materials 0.000 claims description 53
- 150000002367 halogens Chemical class 0.000 claims description 52
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 26
- 125000001424 substituent group Chemical group 0.000 claims description 25
- 208000019901 Anxiety disease Diseases 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 21
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 16
- 208000019906 panic disease Diseases 0.000 claims description 15
- 206010041250 Social phobia Diseases 0.000 claims description 14
- 125000005842 heteroatom Chemical group 0.000 claims description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 13
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
- 208000019022 Mood disease Diseases 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 208000008811 Agoraphobia Diseases 0.000 claims description 7
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 7
- 206010033664 Panic attack Diseases 0.000 claims description 7
- 206010034912 Phobia Diseases 0.000 claims description 7
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 7
- 201000001716 specific phobia Diseases 0.000 claims description 7
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 4
- KXNYEDGRUOMZHR-UHFFFAOYSA-N 4-[2-(2,3,4,5-tetramethylphenoxy)phenyl]piperidine Chemical compound CC1=C(C)C(C)=CC(OC=2C(=CC=CC=2)C2CCNCC2)=C1C KXNYEDGRUOMZHR-UHFFFAOYSA-N 0.000 claims description 3
- KPWSPCJMXLHQAX-UHFFFAOYSA-N 4-[2-(2,4-dimethylphenoxy)phenyl]-1,2,3,6-tetrahydropyridine Chemical compound CC1=CC(C)=CC=C1OC1=CC=CC=C1C1=CCNCC1 KPWSPCJMXLHQAX-UHFFFAOYSA-N 0.000 claims description 3
- YVLMCPPLISKVSZ-UHFFFAOYSA-N 4-[2-(3,4-dimethoxyphenoxy)phenyl]piperidine Chemical compound C1=C(OC)C(OC)=CC=C1OC1=CC=CC=C1C1CCNCC1 YVLMCPPLISKVSZ-UHFFFAOYSA-N 0.000 claims description 3
- AWMJDQHADNOTRT-UHFFFAOYSA-N 4-[2-(3,4-dimethylphenoxy)phenyl]piperidine Chemical compound C1=C(C)C(C)=CC=C1OC1=CC=CC=C1C1CCNCC1 AWMJDQHADNOTRT-UHFFFAOYSA-N 0.000 claims description 3
- TYKRQASZWCXFQZ-UHFFFAOYSA-N 4-[2-(4-chlorophenoxy)phenyl]-1,2,3,6-tetrahydropyridine Chemical compound C1=CC(Cl)=CC=C1OC1=CC=CC=C1C1=CCNCC1 TYKRQASZWCXFQZ-UHFFFAOYSA-N 0.000 claims description 3
- 208000017194 Affective disease Diseases 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- HPXFEUXPYXZZJU-UHFFFAOYSA-N 4-[2-(2-chloro-4-methoxyphenoxy)phenyl]piperidine Chemical compound ClC1=CC(OC)=CC=C1OC1=CC=CC=C1C1CCNCC1 HPXFEUXPYXZZJU-UHFFFAOYSA-N 0.000 claims description 2
- IPJLJXQGHDMTJX-UHFFFAOYSA-N 4-[2-(3,4-dichlorophenoxy)phenyl]piperidine Chemical compound C1=C(Cl)C(Cl)=CC=C1OC1=CC=CC=C1C1CCNCC1 IPJLJXQGHDMTJX-UHFFFAOYSA-N 0.000 claims description 2
- BICITBQSEWFNTK-UHFFFAOYSA-N 4-[2-(4-chlorophenoxy)phenyl]piperidine Chemical compound C1=CC(Cl)=CC=C1OC1=CC=CC=C1C1CCNCC1 BICITBQSEWFNTK-UHFFFAOYSA-N 0.000 claims description 2
- ASBCOPONEBWWAS-UHFFFAOYSA-N 4-[2-(4-fluoro-2-methylphenoxy)phenyl]-1,2,3,6-tetrahydropyridine Chemical compound CC1=CC(F)=CC=C1OC1=CC=CC=C1C1=CCNCC1 ASBCOPONEBWWAS-UHFFFAOYSA-N 0.000 claims description 2
- INFLBAYTEVGBOD-UHFFFAOYSA-N 4-[2-(4-fluoro-2-methylphenoxy)phenyl]piperidine Chemical compound CC1=CC(F)=CC=C1OC1=CC=CC=C1C1CCNCC1 INFLBAYTEVGBOD-UHFFFAOYSA-N 0.000 claims description 2
- CDCYRZUHTIWRSH-UHFFFAOYSA-N 4-[2-(4-fluorophenoxy)phenyl]-1,2,3,6-tetrahydropyridine Chemical compound C1=CC(F)=CC=C1OC1=CC=CC=C1C1=CCNCC1 CDCYRZUHTIWRSH-UHFFFAOYSA-N 0.000 claims description 2
- BXXRQIARNFYYBC-UHFFFAOYSA-N 4-[2-(4-fluorophenoxy)phenyl]piperidine Chemical compound C1=CC(F)=CC=C1OC1=CC=CC=C1C1CCNCC1 BXXRQIARNFYYBC-UHFFFAOYSA-N 0.000 claims description 2
- KLMLKKWVKPDINX-UHFFFAOYSA-N 4-[2-(4-methoxy-2-methylphenoxy)phenyl]piperidine Chemical compound CC1=CC(OC)=CC=C1OC1=CC=CC=C1C1CCNCC1 KLMLKKWVKPDINX-UHFFFAOYSA-N 0.000 claims description 2
- NTEDMHFVJTYUHP-UHFFFAOYSA-N 4-[2-(4-methoxyphenoxy)phenyl]-1,2,3,6-tetrahydropyridine Chemical compound C1=CC(OC)=CC=C1OC1=CC=CC=C1C1=CCNCC1 NTEDMHFVJTYUHP-UHFFFAOYSA-N 0.000 claims description 2
- FBWRRIWYNPHIRT-UHFFFAOYSA-N 4-[2-(4-methoxyphenoxy)phenyl]piperidine Chemical compound C1=CC(OC)=CC=C1OC1=CC=CC=C1C1CCNCC1 FBWRRIWYNPHIRT-UHFFFAOYSA-N 0.000 claims description 2
- CAUWIKSKOFISPD-UHFFFAOYSA-N 4-[2-(4-methylphenoxy)phenyl]-1,2,3,6-tetrahydropyridine Chemical compound C1=CC(C)=CC=C1OC1=CC=CC=C1C1=CCNCC1 CAUWIKSKOFISPD-UHFFFAOYSA-N 0.000 claims description 2
- CJKZVNKHTODIPE-UHFFFAOYSA-N 4-[2-[4-(trifluoromethyl)phenoxy]phenyl]piperidine Chemical compound C1=CC(C(F)(F)F)=CC=C1OC1=CC=CC=C1C1CCNCC1 CJKZVNKHTODIPE-UHFFFAOYSA-N 0.000 claims description 2
- XLINHGWUFRRUIO-UHFFFAOYSA-N 4-[2-[4-chloro-3-(trifluoromethyl)phenoxy]phenyl]piperidine Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(OC=2C(=CC=CC=2)C2CCNCC2)=C1 XLINHGWUFRRUIO-UHFFFAOYSA-N 0.000 claims description 2
- MLNKFRKZSPKGHF-UHFFFAOYSA-N 4-[2-(2,4-dimethylphenoxy)phenyl]piperidine Chemical compound CC1=CC(C)=CC=C1OC1=CC=CC=C1C1CCNCC1 MLNKFRKZSPKGHF-UHFFFAOYSA-N 0.000 claims 1
- FSYSHOTVQBUVEG-UHFFFAOYSA-N 4-[2-(4-methylphenoxy)phenyl]piperidine Chemical compound C1=CC(C)=CC=C1OC1=CC=CC=C1C1CCNCC1 FSYSHOTVQBUVEG-UHFFFAOYSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 15
- 238000000034 method Methods 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 8
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 7
- 125000001153 fluoro group Chemical group F* 0.000 description 7
- 125000005322 morpholin-1-yl group Chemical group 0.000 description 7
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 7
- 125000003226 pyrazolyl group Chemical group 0.000 description 7
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 6
- 125000001309 chloro group Chemical group Cl* 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 230000012154 norepinephrine uptake Effects 0.000 description 5
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 5
- 230000000697 serotonin reuptake Effects 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 4
- 230000036506 anxiety Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 3
- 230000002301 combined effect Effects 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229960002866 duloxetine Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000001050 pharmacotherapy Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229960004688 venlafaxine Drugs 0.000 description 2
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 2
- LLSKXGRDUPMXLC-UHFFFAOYSA-N 1-phenylpiperidine Chemical compound C1CCCCN1C1=CC=CC=C1 LLSKXGRDUPMXLC-UHFFFAOYSA-N 0.000 description 1
- RDRLHHVWGSCUEY-UHFFFAOYSA-N 4-[2-(1,3-benzodioxol-5-yloxy)phenyl]piperidine Chemical compound C1=C2OCOC2=CC=C1OC1=CC=CC=C1C1CCNCC1 RDRLHHVWGSCUEY-UHFFFAOYSA-N 0.000 description 1
- BTNODZPIOAHBEN-UHFFFAOYSA-N 4-[2-(1-benzothiophen-5-yloxy)phenyl]piperidine Chemical compound C1CNCCC1C1=CC=CC=C1OC1=CC=C(SC=C2)C2=C1 BTNODZPIOAHBEN-UHFFFAOYSA-N 0.000 description 1
- DDCQZNJEBDQUJJ-UHFFFAOYSA-N 4-[2-(2,4-dichlorophenoxy)phenyl]piperidine Chemical compound ClC1=CC(Cl)=CC=C1OC1=CC=CC=C1C1CCNCC1 DDCQZNJEBDQUJJ-UHFFFAOYSA-N 0.000 description 1
- NKSNBEMTDZEWIH-UHFFFAOYSA-N 4-[2-(2-chloro-4-methylphenoxy)phenyl]piperidine Chemical compound ClC1=CC(C)=CC=C1OC1=CC=CC=C1C1CCNCC1 NKSNBEMTDZEWIH-UHFFFAOYSA-N 0.000 description 1
- MNJNIDYXXPOAKV-UHFFFAOYSA-N 4-[2-(4-chloro-2-methylphenoxy)phenyl]piperidine Chemical compound CC1=CC(Cl)=CC=C1OC1=CC=CC=C1C1CCNCC1 MNJNIDYXXPOAKV-UHFFFAOYSA-N 0.000 description 1
- SKTFQHRVFFOHTQ-UHFFFAOYSA-N 8-bromo-1,3-dimethyl-7h-purine-2,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Br)=N2 SKTFQHRVFFOHTQ-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Natural products O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000005489 p-toluenesulfonic acid group Chemical class 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
- 230000013275 serotonin uptake Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200300519 | 2003-04-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200505031B true ZA200505031B (en) | 2006-09-27 |
Family
ID=36701494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200505031A ZA200505031B (en) | 2003-04-04 | 2004-04-02 | 4-(2-Phenyloxyphenyl)-piperidine or -1,2,3,6-tetrahy-dropyridine derivatives as serotonin reuptake inhibitors |
Country Status (8)
| Country | Link |
|---|---|
| KR (1) | KR20050119682A (ru) |
| CN (1) | CN1767829A (ru) |
| AR (1) | AR043966A1 (ru) |
| CL (1) | CL2004000726A1 (ru) |
| EA (1) | EA009417B1 (ru) |
| IS (1) | IS7901A (ru) |
| UA (1) | UA81469C2 (ru) |
| ZA (1) | ZA200505031B (ru) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101613347B (zh) * | 2008-06-23 | 2012-07-04 | 中国人民解放军军事医学科学院毒物药物研究所 | 胺类化合物及其医药用途 |
| DK2358674T3 (da) * | 2008-11-14 | 2013-04-08 | Theravance Inc | Fremgangsmåde til fremstilling af 4-[2-(2-fluorphenoxymethyl)phenyl]piperidinforbindelser |
| CN104710345B (zh) * | 2013-12-17 | 2017-09-05 | 江苏恩华药业股份有限公司 | 用于制备4‑（2‑（4‑甲基苯基硫基））苯基哌啶的化合物、其制备方法及应用 |
| CN105294554B (zh) * | 2015-11-18 | 2017-11-07 | 乳源瑶族自治县大众药品贸易有限公司 | 苯基哌嗪衍生物及其使用方法和用途 |
| CN105348204B (zh) * | 2015-11-18 | 2018-09-14 | 乳源瑶族自治县大众药品贸易有限公司 | 1-杂环基-2-(杂芳基硫基)苯衍生物及其使用方法和用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4241071A (en) * | 1977-01-27 | 1980-12-23 | American Hoechst Corporation | Antidepressant (α-phenyl-2-tolyl)azacycloalkanes |
| US4198417A (en) * | 1979-01-10 | 1980-04-15 | American Hoechst Corporation | Phenoxyphenylpiperidines |
| AP2002002481A0 (en) * | 1999-10-13 | 2002-06-30 | Pfizer Prod Inc | Biaryl ether derivatives useful as monoamine reuptake inhibitors. |
| UA81749C2 (ru) * | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | производные фенилпиперазина как ингибиторы обратного захвата серотонинА |
-
2004
- 2004-04-02 KR KR1020057018912A patent/KR20050119682A/ko not_active Application Discontinuation
- 2004-04-02 AR ARP040101132A patent/AR043966A1/es unknown
- 2004-04-02 ZA ZA200505031A patent/ZA200505031B/en unknown
- 2004-04-02 UA UAA200509295A patent/UA81469C2/xx unknown
- 2004-04-02 CN CNA200480008884XA patent/CN1767829A/zh active Pending
- 2004-04-02 CL CL200400726A patent/CL2004000726A1/es unknown
- 2004-04-02 EA EA200501580A patent/EA009417B1/ru not_active IP Right Cessation
-
2005
- 2005-06-20 IS IS7901A patent/IS7901A/is unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UA81469C2 (en) | 2008-01-10 |
| IS7901A (is) | 2005-06-20 |
| KR20050119682A (ko) | 2005-12-21 |
| CN1767829A (zh) | 2006-05-03 |
| EA009417B1 (ru) | 2007-12-28 |
| EA200501580A1 (ru) | 2006-04-28 |
| CL2004000726A1 (es) | 2005-05-20 |
| AR043966A1 (es) | 2005-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1077940B1 (en) | 4-phenylpiperidines for the treatment of pruritic dermatoses | |
| AU754745B2 (en) | Derivatives of azetidine and pyrrolidine | |
| US20080033011A1 (en) | Novel benzo[d][1,3]-dioxol derivatives | |
| CZ257892A3 (en) | Derivative of 1,4-benzodioxan, process of its preparation and a pharmaceutical preparation in which said derivative is comprised | |
| US6403573B1 (en) | Compounds of azetidine and pyrrolidin | |
| JPH0739388B2 (ja) | ピペリジン誘導体 | |
| US4935414A (en) | New indolylpropanols, processes for their preparation and their use, and preparations containing the compounds | |
| JP5416749B2 (ja) | ベンジルピペリジン化合物 | |
| EP2521714B1 (en) | Aromatic sulfone compounds useful in the treatment of central nervous disorders | |
| ZA200505031B (en) | 4-(2-Phenyloxyphenyl)-piperidine or -1,2,3,6-tetrahy-dropyridine derivatives as serotonin reuptake inhibitors | |
| EP1635828B1 (en) | 4-(2-phenyloxyphenyl)-piperidine or -1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors | |
| RU2232753C2 (ru) | 4-замещенные пиперидины, фармацевтическая композиция на их основе и способ лечения заболеваний центральной нервной системы | |
| US20070173522A1 (en) | 4-(2-Phenylsulfanyl-phenyl)-1,2,3,6- tetrahydropyridine derivatives as serotonin reuptake inhibitors | |
| WO2005073183A1 (ja) | アリールスルフィド誘導体 | |
| US7084301B2 (en) | Tamsulosin derivative | |
| EP0438533A1 (en) | Muscarinic receptor antagonists | |
| AU2003301277B2 (en) | 3-(cyclopenten-1-yl)-benzyl- or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia | |
| US7504419B2 (en) | Diastereomers of 4-aryloxy-3-hydroxypiperidines | |
| WO2014190942A1 (zh) | 一类吲哚类化合物、其制备方法、药物组合物及应用 | |
| US8778970B2 (en) | Benzyl piperidine compound | |
| JP2005523936A (ja) | タムスロシン誘導体 |